Hims & Hers Health shares drop over 3% after Hers brand launches in Australia and class action concerns

Traders Union
All News
Stocks
Hims & hers slides 3.31% today

Highlights

Hims & Hers Health completed the Hers brand launch in Australia and will report third quarter 2026 earnings on November 9, 2026.
Shareholder law firms have referenced the company amid ongoing class action filings, with the stock trading well below its 52-week high.
Shares of Hims & Hers Health closed at $28.75, down 3.31%, and are expected to trade between $26.65 and $30.85 over the next five sessions with a 67% chance of an upward move.

Class action news and law firm scrutiny weigh on sentiment

Hims & Hers Health announced the completion of the Hers brand launch in Australia and confirmed it will report its third quarter 2026 earnings after the market close on November 9, 2026. The company has also been referenced in announcements by shareholder-focused law firms related to ongoing class action filings. These developments have occurred alongside the stock remaining at a significant discount to its 52-week high, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes ongoing selling pressure as Hims & Hers Health trades below both the 20-day and 50-day moving averages. He observes that the stock’s decline is exacerbated by legal news and sentiment-driven volatility following the Hers launch in Australia. Technical signals remain mixed, but the presence of class action filings can weigh on both retail and institutional confidence. Kharitonov is cautious about the company's short-term outlook, highlighting that momentum oscillators diverge and newsflow is negatively biased. "Until legal and news risks resolve, I expect sellers to dominate and would remain defensive around key support levels," he states.

Viktoras Karapetjanc, expert at Traders Union, sees Hims & Hers Health maintaining a bullish structure above the 200-day moving average. He emphasizes that the company’s expansion into Australia and upcoming earnings are positive fundamental drivers. Karapetjanc notes that sentiment may recover quickly given the high probability of an upward move predicted in forecasts. Forward-looking investors have opportunities as technicals point to further upside if resistance at $28.92 is cleared. "I believe the long-term growth story remains intact, and further gains toward the upper range are likely," he says.

Sholanke Dele, market strategist, views sentiment on Hims & Hers Health as fragile. He highlights that recurring legal concerns and proximity to session lows cloud confidence. Macro volatility and ongoing class action risks create headwinds despite recent brand expansion. "Traders should be wary of false rebounds and stay risk-averse until legal clouds clear," Dele concludes.

Mixed momentum as short-term weakness meets long-term support

Hims & Hers Health is trading below both its 20-day and 50-day moving averages at $29.22 and $29.49, but remains above the 200-day at $27.35. This structure highlights near- and medium-term pressure from sellers, while the longer-term technical alignment stays bullish due to the 50/200-day crossover. Key resistance stands at $28.92, with support at the week’s low of $27.53. Momentum signals are mixed: MACD is bullish, ADX is neutral, and RSI is mid-range but leans "Buy." Stochastic RSI gives a strong sell, CCI is neutral, Bull/Bear Power is positive at 0.85 but flagged as overbought, and the Awesome Oscillator is on the buy side. Price action is close to the session low amid 4.67% intraday volatility, and momentum oscillators reveal notable divergence.

Earlier, analysts noted that Hims & Hers Health faced heightened regulatory and litigation risks, contributing to technical pressure and underscoring the need to monitor ongoing developments. With the latest downward break below both the 20-day and 50-day moving averages as earnings and shareholder actions approach, traders should closely watch for any shift in momentum or a breakout beyond the current $26.65–$30.85 volatility band.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.